...
首页> 外文期刊>Health Research Policy and Systems >Stakeholders’ perspectives on access-to-medicines policy and research priorities in Latin America and the Caribbean: face-to-face and web-based interviews
【24h】

Stakeholders’ perspectives on access-to-medicines policy and research priorities in Latin America and the Caribbean: face-to-face and web-based interviews

机译:利益相关者对拉丁美洲和加勒比地区获得药物的政策和研究重点的观点:面对面和基于网络的访谈

获取原文
           

摘要

Background This study aims to rank policy concerns and policy-related research issues in order to identify policy and research gaps on access to medicines (ATM) in low- and middle-income countries in Latin America and the Caribbean (LAC), as perceived by policy makers, researchers, NGO and international organization representatives, as part of a global prioritization exercise. Methods Data collection, conducted between January and May 2011, involved face-to-face interviews in El Salvador, Colombia, Dominican Republic, and Suriname, and an e-mail survey with key-stakeholders. Respondents were asked to choose the five most relevant criteria for research prioritization and to score policy/research items according to the degree to which they represented current policies, desired policies, current research topics, and/or desired research topics. Mean scores and summary rankings were obtained. Linear regressions were performed to contrast rankings concerning current and desired policies (policy gaps), and current and desired research (research gaps). Results Relevance, feasibility, and research utilization were the top ranked criteria for prioritizing research. Technical capacity, research and development for new drugs, and responsiveness, were the main policy gaps. Quality assurance, staff technical capacity, price regulation, out-of-pocket payments, and cost containment policies, were the main research gaps. There was high level of coherence between current and desired policies: coefficients of determination (R2) varied from 0.46 (Health system structure; r = 0.68, P <0.01) to 0.86 (Sustainable financing; r = 0.93, P <0.01). There was also high coherence between current and desired research on Rational selection and use of medicines (r = 0.71, P <0.05, R2 = 0.51), Pricing/affordability (r = 0.82, P <0.01, R2 = 0.67), and Sustainable financing (r = 0.76, P <0.01, R2 = 0.58). Coherence was less for Health system structure (r = 0.61, P <0.01, R2 = 0.38). Conclusions This study combines metrics approaches, contributing to priority setting methodology development, with country and regional level stakeholder participation. Stakeholders received feedback with the results, and we hope to have contributed to the discussion and implementation of ATM research and policy priorities in LAC.
机译:背景技术本研究旨在对政策关注点和与政策相关的研究问题进行排名,以便找出拉丁美洲和加勒比地区(LAC)中低收入国家在获取药品(ATM)方面的政策和研究差距,决策者,研究人员,非政府组织和国际组织的代表,作为全球优先排序活动的一部分。方法2011年1月至2011年5月之间进行的数据收集涉及萨尔瓦多,哥伦比亚,多米尼加共和国和苏里南的面对面访谈,以及与主要利益相关者的电子邮件调查。要求受访者选择五个最相关的研究优先级标准,并根据他们代表当前政策,所需政策,当前研究主题和/或所需研究主题的程度对政策/研究项目进行评分。获得了平均分数和摘要排名。进行线性回归以对比有关当前和期望的政策(政策差距)以及当前和期望的研究(研究差距)的排名。结果相关性,可行性和研究利用率是确定研究优先级的最高标准。技术能力,新药的研发和响应能力是主要的政策空白。主要的研究空白是质量保证,人员技术能力,价格监管,自付费用和成本控制政策。当前政策与期望政策之间具有高度的一致性:确定系数(R2)从0.46(卫生系统结构; r = 0.68,P <0.01)到0.86(可持续融资; r = 0.93,P <0.01)。在当前和理想的药物合理选择和使用研究(r = 0.71,P <0.05,R2 = 0.51),定价/负担能力(r = 0.82,P <0.01,R2 = 0.67)和可持续研究之间也具有高度的一致性。融资(r = 0.76,P <0.01,R2 = 0.58)。卫生系统结构的连贯性较小(r = 0.61,P <0.01,R2 = 0.38)。结论本研究结合了指标方法,有助于优先级确定方法的发展,并具有国家和地区级利益相关者的参与。利益相关者收到了有关结果的反馈,我们希望为LAC的ATM研究和政策重点的讨论和实施做出贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号